BioCryst Pharmaceuticals Files 8-K
Ticker: BCRX · Form: 8-K · Filed: Oct 2, 2024 · CIK: 882796
Sentiment: neutral
Topics: disclosure, regulatory
Related Tickers: BCRX
TL;DR
BioCryst filed an 8-K on Oct 2nd, mostly procedural stuff, no major news.
AI Summary
BioCryst Pharmaceuticals, Inc. filed an 8-K on October 2, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the reporting of these items.
Why It Matters
This filing indicates BioCryst Pharmaceuticals is providing updates or disclosures required by the SEC, which could relate to financial statements or regulatory information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- October 2, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by BioCryst Pharmaceuticals?
The primary purpose is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
On what date was this 8-K filing made?
The filing was made on October 2, 2024.
What is BioCryst Pharmaceuticals' state of incorporation?
BioCryst Pharmaceuticals is incorporated in Delaware.
What is the principal executive office address for BioCryst Pharmaceuticals?
The principal executive office is located at 4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703.
Does this filing announce any new product approvals or significant financial results?
This filing does not specify any new product approvals or significant financial results; it primarily concerns disclosures and exhibits.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-10-02 07:06:38
Filing Documents
- f8k_100224.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 6KB
- 0001171843-24-005439.txt ( ) — 218KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_100224_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 2, 2024, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing the enrollment of the first participant in a Phase 1 trial evaluating BCX17725, a potent and selective investigational kallikrein 5 ("KLK5") inhibitor designed to provide best-in-class disease-modifying treatment for people with Netherton syndrome. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated October 2, 2024 entitled "BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioCryst Pharmaceuticals, Inc. Date: October 2, 2024 By: /s/ Alane Barnes Alane Barnes Chief Legal Officer